Goal‐Directed Rehabilitation Versus Standard Care for Individuals with Hereditary Cerebellar Ataxia: A Multicenter, Single‐Blind, Randomized Controlled Superiority Trial
Authors:
- 9 November 2024
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 97 (3) , 409-424
Abstract
Objective: Rehabilitation is thought to reduce ataxia severity in individuals with hereditary cerebellar ataxia (HCA). This multicenter, randomized controlled superiority trial aimed to examine the efficacy of a 30‐week goal‐directed rehabilitation program compared with 30 weeks of standard care on function, ataxia, health‐related quality of life, and balance in individuals with an HCA.Methods: Individuals with an autosomal dominant or recessive ataxia (aged ≥15 years) were enrolled at 5 sites in Australia. Participants were randomized (1:1) to receive rehabilitation (6 weeks of outpatient physiotherapy followed by a 24‐week home exercise program) (n = 39) or continued their usual activity (n = 37). The primary outcome measure was the motor domain of the Functional Independence Measure (mFIM) at 7 weeks. Secondary outcomes included the Scale for the Assessment and Rating of Ataxia (SARA) and the SF‐36v2, assessed at 7, 18, and 30 weeks. Outcome assessors were blinded to treatment allocation.Results: Seventy‐one participants (rehabilitation, 37; standard‐care, 34) were included in the intention‐to‐treat analysis. At 7 weeks, mFIM (mean difference 2.26, 95% confidence interval [CI]: 0.26 to 4.26, p = 0.028) and SARA (−1.21, 95% CI: −2.32 to −0.11, p = 0.032) scores improved after rehabilitation compared with standard care. Compared with standard care, rehabilitation improved SARA scores at 30 weeks (mean difference −1.51, 95% CI: −2.76 to −0.27, p = 0.017), but not mFIM scores (1.74, 95% CI: −0.32 to 3.81, p = 0.098). Frequent adverse events in both groups were fatigue, pain, and falls.Interpretation: Goal‐directed rehabilitation improved function at 7 weeks, with improvement in ataxia and health‐related quality of life maintained at 30 weeks in individuals with HCA, beyond that of standard care. ANN NEUROL 2025;97:409–424Keywords
Funding Information
- Department of Health and Aged Care, Australian Government (APP1143098, APP1152226)
This publication has 38 references indexed in Scilit:
- FARS‐ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important ChangeMovement Disorders, 2024
- Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia PatientsAnnals of Neurology, 2023
- The inherited cerebellar ataxias: an updateJournal of Neurology, 2022
- Home Aerobic Training for Cerebellar Degenerative Diseases: a Randomized Controlled TrialThe Cerebellum, 2022
- Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)Annals of Neurology, 2020
- Neurorehabilitation Improves the Motor Features in Prodromal SCA2: A Randomized, Controlled TrialMovement Disorders, 2019
- Effects of Physical Rehabilitation in Patients with Spinocerebellar Ataxia Type 7The Cerebellum, 2019
- Neurorehabilitation therapy in spinocerebellar ataxia type 2: A 24‐week, rater‐blinded, randomized, controlled trialMovement Disorders, 2018
- Mutational Origin of Machado-Joseph Disease in the Australian Aboriginal Communities of Groote Eylandt and YirrkalaArchives of Neurology, 2012
- Long‐term effects of coordinative training in degenerative cerebellar diseaseMovement Disorders, 2010